X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. (XFOR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
xfor · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for X4 Pharmaceuticals, Inc. (XFOR) measures how much investors pay for each dollar of the company's trailing earnings. XFOR's current PE ratio of N/A is calculated by dividing its stock price of $3.77 by its TTM earnings per share of -$0.79.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
X4 Pharmaceuticals, Inc.You XFOR | $356M | N/A | — | -$0.79 |
 Aligos Therapeutics, Inc. ALGS | $32M | N/A | — | -$2.45 |
 FibroGen, Inc. FGEN | $37M | 0.19x | — | $45.38 |
 INmune Bio, Inc. INMB | $34M | N/A | — | -$1.73 |
 Karyopharm Therapeutics Inc. KPTI | $201M | N/A | — | -$17.93 |
 Kezar Life Sciences, Inc. KZR | $54M | N/A | — | -$7.66 |
 Mersana Therapeutics, Inc. MRSN | $145M | N/A | — | -$14.12 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.87 | — | |
2024-12-31 FY2024 | — | $-5.59 | — | |
2023-12-31 FY2023 | — | $-17.07 | — | |
2022-12-31 FY2022 | — | $-44.33 | — | |
2021-12-31 FY2021 | — | $-103.34 | — | |
2020-12-31 FY2020 | — | $-92.84 | — | |
2019-12-31 FY2019 | — | $-137.40 | — | |
2018-12-31 FY2018 | — | $-13058.06 | — | |
2017-12-31 FY2017 | — | $-17745.94 | — | |
2016-12-31 FY2016 | — | $-1735.93 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for X4 Pharmaceuticals, Inc. (XFOR) measures how much investors pay for each dollar of the company's trailing earnings. XFOR's current PE ratio of N/A is calculated by dividing its stock price of $3.77 by its TTM earnings per share of -$0.79.
Frequently asked questions
XFOR pe ratio · 6 questionsXFOR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.77 and TTM EPS of -$0.79. Data sourced from Financial Modeling Prep via XFOR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · X4 Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09